Skip to main content
. 2022 Jan 20;399(10323):461–472. doi: 10.1016/S0140-6736(22)00055-1

Figure 2.

Figure 2

Kaplan-Meier plots of efficacy of the SCB-2019 plus CpG and alum vaccine candidate against symptomatic COVID-19

Cumulative incidence of RT-PCR-confirmed COVID-19 of any severity with onset at least 14 days after the second dose of SCB-2019 plus CpG and alum or placebo in the per-protocol population with no previous exposure to SARS-CoV-2 (A) and in the full analysis set population (B).